NAPROXEN SODIUM tablet

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

NAPROXEN SODIUM (UNII: 9TN87S3A3C) (NAPROXEN - UNII:57Y76R9ATQ)

Disponible depuis:

Keltman Pharmaceuticals Inc.

DCI (Dénomination commune internationale):

NAPROXEN SODIUM

Composition:

NAPROXEN SODIUM 550 mg

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

Carefully consider the potential benefits and risks of Naproxen Sodium Tablets, USP and other treatment options before deciding to use Naproxen Sodium Tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. Naproxen as naproxen sodium tablets are indicated: • For the relief of the signs and symptoms of rheumatoid arthritis • For the relief of the signs and symptoms of osteoarthritis • For the relief of the signs and symptoms of ankylosing spondylitis • For the relief of the signs and symptoms of juvenile arthritis • For relief of the signs and symptoms of tendonitis • For relief of the signs and symptoms of bursitis • For relief of the signs and symptoms of acute gout • For the management of pain • For the management of primary dysmenorrhea Naproxen Sodium Tablets, USP are contrain

Descriptif du produit:

Naproxen Sodium Tablets, USP 275 mg are blue, oval, biconvex, film coated tablets debossed “IP193” on obverse and plain on reverse. Naproxen Sodium Tablets, USP 550 mg are blue, oval, biconvex, film coated tablets debossed “IP” bisect “194” on obverse and plain on reverse. They are supplied by Keltman Pharmaceuticals Inc. as follows: Store at 15° to 30°C (59° to 86°F) in well-closed containers.

Statut de autorisation:

Abbreviated New Drug Application

Résumé des caractéristiques du produit

NAPROXEN SODIUM - NAPROXEN SODIUM TABLET
KELTMAN PHARMACEUTICALS INC.
----------
NAPROXEN SODIUM TABLETS
RX ONLY
CARDIOVASCULAR RISK• NSAIDs may cause an increased risk of serious
cardiovascular thrombotic events,
myocardial infarction, and stroke, which can be fatal. This risk may
increase with duration of use. Patients
with cardiovascular disease or risk factors for cardiovascular disease
may be at greater risk (see
WARNINGS).• Naproxen as Naproxen Sodium Tablets, USP is
contraindicated for the treatment of peri-
operative pain in the setting of coronary artery bypass graft (CABG)
surgery (see
WARNINGS).GASTROINTESTINAL RISK• NSAIDs cause an increased risk of
serious gastrointestinal adverse
events including bleeding, ulceration, and perforation of the stomach
or intestines, which can be fatal.
These events can occur at any time during use and without warning
symptoms. Elderly patients are at
greater risk for serious gastrointestinal events (see WARNINGS).
DESCRIPTION
Naproxen is a propionic acid derivative related to the arylacetic acid
group of nonsteroidal anti-
inflammatory drugs.
The chemical name for naproxen sodium is (S)-6-methoxy-
-methyl-2-naphthalene acetic acid, sodium
salt. Naproxen sodium has the following structure:
Naproxen sodium has a molecular weight of 252.23 and a molecular
formula of C14H13NaO3.
Naproxen sodium is a white to creamy white, crystalline solid, freely
soluble in water at neutral pH.
Naproxen Sodium Tablets, USP are available as blue tablets containing
275 mg of naproxen sodium and
as blue tablets containing 550 mg of naproxen sodium. The inactive
ingredients are
croscarmellose sodium, macrogol, magnesium stearate, polyvinly
alcohol, povidone, talc, titanium
dioxide and FD&C Blue #2.
CLINICAL PHARMACOLOGY
PHARMACODYNAMICS
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with
analgesic and antipyretic properties.
The sodium salt of naproxen has been developed as a more rapidly
absorbed formulation of naproxen
for use as an analgesic. The mechanism of action of the